Sartorius Stedim Biotech 2020 Virtual AnnualShareholder`s Meeting
Presentation of the CEO and Chairman of the BoardJune 24, 2020
We have coped well with the first phase of the pandemic
Our priorities
1.Safety first: Responsibility for over 6,300 employees
2.Ensure delivery capability for our customers
3.Secure financial stability and strength
Challenges
Risks of a second wave of infection, global recession, adaption to longer term changes
Remote integration of acquired businesses
2
Our products contribute to the development of effective vaccines
Thank you to our customers for their trust and to all employees and suppliers for keeping our business running!
2019 was another year of dynamic profitable growth
Strong 2019 with significant double-digit growth rates-upgraded forecast exceeded
Two strategically important acquisitions
Position as a leading international technology partner of the biopharma industry expanded
5
Attachments
- Original document
- Permalink
Disclaimer
Sartorius AG published this content on 24 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 June 2020 07:18:01 UTC